Boundless Bio Announces Pipeline and Leadership Updates
Provided By GlobeNewswire
Last update: Dec 12, 2024
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial
Third ecDTx program advancing, with plans for development candidate nomination by mid-2025
Read more at globenewswire.comNASDAQ:BOLD (2/24/2025, 11:38:55 AM)
1.88
-0.08 (-4.08%)
Find more stocks in the Stock Screener
